Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

• Wondering whether Innoviva’s current share price reflects its true worth, or if the stock might be mispriced.

• After some shorter term share price weakness, with the stock down 0.4% over the past week and 3.7% over the past month, Innoviva is still up 15.2% year to date and 23.0% over the last year.

• Those moves sit against a backdrop of ongoing attention on Innoviva’s position in the pharmaceuticals space and on how investors weigh its portfolio and balance sheet against sector peers. Recent coverage has focused on how the stock fits into broader healthcare allocations and whether its current pricing aligns with its…